MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$77,787K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable securit...
Other income, net
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Personnel-related expenses
Program-specific expenses-Relutr...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Collaboration revenue
-
-
0
0
Program-specific expenses-Ulixacaltamide
13,299
19,103
9,665
11,644
Program-specific expenses-Vormatrigine
12,878
20,494
21,470
20,899
Program-specific expenses-Relutrigine
13,979
12,854
15,100
14,965
Program-specific expenses-Elsunersen
8,141
3,197
2,536
2,219
Program-specific expenses-Other Early State Assets
5,471
3,242
2,355
3,142
Personnel-related expenses
18,943
17,730
27,660
12,116
Stock-based compensation expense
11,309
17,112
9,938
7,447
Depreciation expense
33
39
28
19
Other segment expenses
12,851
12,089
8,292
5,908
Interest income
-
-
-
4,425
Other income, net
13,184
13,299
22,930
-
Net loss
-83,720
-92,561
-88,911
-73,934
Depreciation expense
33
39
28
19
Stock-based compensation expense
11,309
17,112
9,938
7,447
Non-cash operating lease expense
319
197
271
263
Amortization of premiums and discounts on marketable securities, net
689
655
671
705
Non-cash collaboration and license agreement expense
-
-
0
0
Other non-cash adjustments
-
-
7
-
Prepaid expenses and other current assets
2,860
-672
4,894
1,383
Accounts payable
-7,882
6,530
-6,194
1,987
Accrued expenses
6,939
-17,385
14,428
1,578
Operating lease liabilities
-348
-101
-326
-933
Deferred revenue
-
-
0
0
Other
-643
0
13
-10
Net cash used in operating activities
-77,542
-86,152
-76,325
-65,057
Capitalized internal-use software costs
773
-
-
-
Purchases of property and equipment
245
62
0
0
Purchases of marketable securities
77,268
486,782
390,275
75,133
Maturities of marketable securities
89,268
142,569
61,884
125,546
Net cash used in investing activities
10,982
-344,275
-328,391
50,413
Proceeds from stock offerings, net of issuance costs-Follow On Offering
0
621,235
567,115
0
Proceeds from stock offerings, net of issuance costs-License And Collaboration Agreement
-
-
0
0
Proceeds from stock offerings, net of issuance costs-At The Market Offering
0
0
34,610
6,000
Payments of tax withholdings related to vesting of restricted stock units
310
12,923
819
52
Proceeds from exercise of options and employee stock purchase plan purchases
-
-
11,612
808
Proceeds from exercise of stock options and employee stock purchase plan purchases
4,882
1,119
-
-
Net cash provided by financing activities
4,572
609,431
612,518
6,756
Increase (decrease) in cash, cash equivalents and restricted cash
-61,988
179,004
207,802
-7,888
Cash, cash equivalents and restricted cash, beginning of period
149,943
149,943
-
215,788
Cash, cash equivalents and restricted cash, end of period
474,761
-
-
-
Cash and cash equivalents
474,761
-
-
-
Restricted cash
0
-
-
-
Total cash, cash equivalents and restricted cash
474,761
536,749
-
149,943
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of marketable
securities
$89,268K
(-28.75%↓ Y/Y)
Proceeds from exercise of
stock options and...
$4,882K
(471.66%↑ Y/Y)
Net cash used in
investing activities
$10,982K
(133.11%↑ Y/Y)
Net cash provided by
financing activities
$4,572K
(-94.48%↓ Y/Y)
Canceled cashflow
$78,286K
Canceled cashflow
$310K
Increase (decrease) in
cash, cash...
-$61,988K
(-6.96%↓ Y/Y)
Canceled cashflow
$15,554K
Stock-based compensation
expense
$11,309K
(-31.69%↓ Y/Y)
Accrued expenses
$6,939K
(244.38%↑ Y/Y)
Non-cash operating lease
expense
$319K
(-36.96%↓ Y/Y)
Depreciation expense
$33K
(-64.52%↓ Y/Y)
Purchases of marketable
securities
$77,268K
(-51.22%↓ Y/Y)
Capitalized internal-use
software costs
$773K
Purchases of property and
equipment
$245K
(337.50%↑ Y/Y)
Payments of tax
withholdings related to...
$310K
(-74.55%↓ Y/Y)
Net cash used in
operating activities
-$77,542K
(27.99%↑ Y/Y)
Canceled cashflow
$18,600K
Other income, net
$13,184K
Net loss
-$83,720K
(40.38%↑ Y/Y)
Canceled cashflow
$13,184K
Accounts payable
-$7,882K
(-148.34%↓ Y/Y)
Prepaid expenses and
other current assets
$2,860K
(141.35%↑ Y/Y)
Amortization of premiums and
discounts on marketable...
$689K
(-68.91%↓ Y/Y)
Other
-$643K
(-21333.33%↓ Y/Y)
Operating lease
liabilities
-$348K
(43.32%↑ Y/Y)
Personnel-related expenses
$18,943K
(-24.05%↓ Y/Y)
Program-specific
expenses-Relutrigine
$13,979K
(-12.00%↓ Y/Y)
Program-specific
expenses-Ulixacaltamide
$13,299K
(-68.26%↓ Y/Y)
Program-specific
expenses-Vormatrigine
$12,878K
(-59.36%↓ Y/Y)
Other segment
expenses
$12,851K
(-15.06%↓ Y/Y)
Stock-based compensation
expense
$11,309K
(-31.69%↓ Y/Y)
Program-specific
expenses-Elsunersen
$8,141K
(291.77%↑ Y/Y)
Program-specific expenses-Other
Early State Assets
$5,471K
(116.93%↑ Y/Y)
Depreciation expense
$33K
(-64.52%↓ Y/Y)
Buy us a coffee
Praxis Precision Medicines, Inc. (PRAX)
Praxis Precision Medicines, Inc. (PRAX)